Biotech firms moving at unprecedented speed to develop COVID-19 vaccine
Updated: 2020-11-18 13:35:48 KST
The World Health Organization has so far listed 202 COVID-19 vaccine candidates, 47 of which are currently undergoing clinical human trials.
At least ten are in the third and last phase of testing, most of which are being developed by American or Chinese companies.
On Monday, U.S. pharmaceutical giant Moderna said its experimental vaccine was 94.5 percent effective at preventing the virusduring a preliminary analysis of its phase three trial.
It also said the vaccine only requires standard refrigerator temperatures of two to eight degrees Celsius for 30 days, and can be stored for up to six months at minus 20 degrees, making it more readily available to all.
The results came a matter of days after Pfizer made a similar announcement.
Pfizer earlier reported that its potential coronavirus vaccine had an efficacy rate of more than 90 percent.
The U.S. company is moving fast in the vaccine race, reporting it will soon seek emergency authorization for its vaccine.
At a virtual conference hosted by the New York Times on Tuesday, Pfizer said it was preparing for submissions without specifying the exact timing of when it will file them with the FDA.
Other pharmaceutical companies across the globe are also speeding up their efforts to fight the pandemic, which has infected over 55 million people worldwide.
Min Suk-hyen, Arirang News.